Pamela Ann Connealy - 31 Mar 2025 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
CFO & COO
Signature
/s/ Pamela Connealy
Issuer symbol
PYXS
Transactions as of
31 Mar 2025
Net transactions value
+$405,880
Form type
4
Filing time
02 Apr 2025, 08:56:28 UTC
Previous filing
23 Dec 2024
Next filing
26 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to Buy) Award $405,880 +414,163 $0.9800 414,163 31 Mar 2025 Common Stock 414,163 $0.9800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31, 2025 and the remainder vesting in 36 equal monthly installments thereafter subject to the reporting person's continued emmployment through the applicable vesting date.